大宏立(300865.SZ)擬新設三家子公司
格隆匯 11 月 9日丨大宏立(300865.SZ)公佈,公司於2020年11月9日分別召開了第三屆董事會第十五次會議、第三屆監事會第十次會議,會議審議通過了《關於對外投資的公告的議案》,同意擬在成都市高新區新設立兩家子公司,分別是成都大宏立供應鏈投資有限公司(註冊資本5000萬元)、成都大宏立新材料科技有限公司(註冊資本5000萬元);在成都市大邑縣新設立一家子公司,成都大宏立機電安裝有限公司(註冊資本800萬元)。
根據公司經營計劃和戰略發展需要,公司新設立的三家子公司,有利於增強公司的競爭能力。但是新設立的子公司短期內不能產生經濟效益,預計對公司2020年度的財務狀況和經營成果不會產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.